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Open aSummary
Background: We aimed to investigate the results of anti-tumor necrosis factor (TNF) therapy in
patients with a previous history of tuberculosis (TB).
Methods: A total of 101 patients with a previous history of TB receiving TNF antagonists be-
tween December 2004 and September 2012 at the Asan Medical Center in South Korea were
retrospectively analyzed.
Results: The mean age of the 101 subjects was 40.4  16.0 years and 51 patients (50.5%) were
male. The underlying immune-mediated inflammatory diseases (IMIDs) were Crohn’s disease in
55 (54.5%), rheumatoid arthritis in 27 (26.7%), and ankylosing spondylitis in 13 (12.9%) patients.
Chest radiography findings were suggestive of previous TB lesions in 33 (32.7%) patients. The
rates of positivity in the tuberculin skin test and interferon-gamma release assay were 21.8%
(22/101) and 44.6% (45/101), respectively. Latent TB infection (LTBI) treatment was initiated
in 11 subjects (10.9%) based on previous inappropriate anti-TB treatments (n Z 10) or recent
TB contact history (nZ 1), irrespective of the LTBI test results. The median follow-up durationulmonary & Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388-
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1798 K.-W. Jo et al.after the initiation of TNF antagonist therapy was 31.5 months. Active TB developed, six years
after the initiation of TNF antagonist, in one patient (1.0%) who had not received LTBI treat-
ment. The incidence rate of TB was calculated at 336 per 100,000 person-year (PY).
Conclusions: Patients with IMIDs who have a previous history of TB can be treated with TNF an-
tagonists with an acceptable incidence of TB, if LTBI treatment is performed based on clinical
judgments including the adequacy of previous anti-TB treatment and recent contact history.
ª 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Tumor necrosis factor (TNF) antagonists are increasingly
used to treat patients with immune-mediated inflammatory
diseases (IMIDs), including rheumatoid arthritis (RA),
ankylosing spondylitis (AS), Crohn’s disease (CD), and ul-
cerative colitis (UC) [1]. Because TNF is an essential
component of host defenses against Mycobacterium
tuberculosis, patients treated with TNF antagonists show
an increased incidence of tuberculosis (TB), mostly due to
the reactivation of latent TB infection (LTBI) [2]. Reac-
tivation of LTBI can be considerably reduced by screening
patients with IMIDs for LTBI before initiating treatment with
TNF antagonists, and by promptly initiating appropriate
prophylactic therapy if needed [1,3e5].
Current diagnostic tests for LTBI, including tuberculin
skin tests (TST) and/or interferon-gamma release assays
(IGRAs), are not recommended for patients with a previous
history of TB because these patients are likely to be posi-
tive, even in the absence of current infection, and the re-
sults of these tests do not affect the decision to treat LTBI.
Accordingly, the British Thoracic Society (BTS) has recom-
mended that patients with a history of TB who previously
received adequate treatment can begin TNF antagonists
without LTBI treatment [6]. However, patients in a TB-
prevalent country can become reinfected after comple-
tion of a previous treatment. In addition, the adequacy of
previous TB treatment may be unclear if patients have
received treatment many years earlier. Clinicians are also
concerned about prescribing TNF antagonists in the
absence of LTBI treatment when chest X-ray (CXR) shows
lesions indicative of TB sequalae lesions, even if previous
anti-TB treatments were adequate. To date, however, few
studies have analyzed the use of TNF antagonists in patients
with a previous history of TB.
This study was designed to investigate 1) the percentage
of patients receiving LTBI treatment before beginning anti-
TNF treatment, 2) factors influencing the decision to
initiate LTBI treatment, and 3) the incidence of TB during
anti-TNF therapy in patients with a previous TB history in
South Korea, a country with an intermediate TB burden (92
per 100,000 person-year(PY)) [7].Methods
Study patients
Overall, between December, 2004, and September, 2012,
1279 consecutive patients with IMIDs were screened at theAsan Medical Center, a 2700-bed referral hospital in Seoul,
South Korea, for LTBI before starting treatment with TNF
antagonists. Of these cases, 132 patients (10.3%) had a
previous history of anti-TB treatment irrespective of the
confirmation of TB diagnosis. During screening, three of
these patients (2.3%) were diagnosed with active pulmo-
nary TB and were therefore excluded from further analysis.
Of the remaining 129 patients, 101 were started on a TNF
antagonist therapy. The decision not to use TNF-a inhibitors
in 28 patients was based on their IMID status, not on their
TB infection status. The clinical outcomes in these 101
patients were retrospectively analyzed in December 2012.
RA and AS were diagnosed using previously proposed
criteria [8,9]. CD and UC were diagnosed based on a com-
posite of endoscopic, radiographic, and pathologic findings
as described previously [10].
Our current study protocol was approved by the Insti-
tutional Review Board of the Asan Medical Center, which
waived the requirement for informed consent due to the
retrospective nature of the analysis. However, some of our
study subjects who had been evaluated in a previous study
provided informed consent for TST and IGRA tests [1,5].
LTBI screening methods
Themedical histories assessed at screening included current
symptoms, a prior history of treatment for TB, the presence
of underlying disease, and recent contact with individuals
with active pulmonary TB. CXR, TST, and IGRA were per-
formed on the same day that the patient’s history was taken.
Patients with CXR abnormalities suggestive of previous TB
sequelae, such as fibrostreaky lesions or multiple calcified
nodules in the upper lobe, were assessed using a sputum
acid-fast bacilli (AFB) smear/culture to rule out active TB. In
addition, present and former CXR results were compared to
determine the presence of newly developed lesions.
Each TSTwas performed via the intradermal injection of 2
tuberculin units of purified protein derivative (PPD) RT23
(Statens Serum Institute, Copenhagen, Denmark) into the
forearm using the Mantoux technique [11]. Reactions were
evaluated 48e72 h later, with positive results defined as in-
durations of10mm in the transverse diameter according to
theKoreanGuideline for Tuberculosis [12]. At our institution,
both kinds of IGRA were used sequentially for LTBI screening
during the study period. T-SPOT.TB (T-SPOT; Oxford
Immunotec, Abingdon, UK) tests were performed up to July
2011 (nZ 72) and QuantiFERON TB-Gold In Tube (QFT-GIT;
Cellestis Ltd, Carnegie, Australia) tests have been used since
then (nZ 29). A T-SPOT assay result was defined as positive
when the number of spots in the TB-antigen well minus the
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QFT-GITassay is performed in two stages, in accordancewith
the manufacturer’s instructions. One milliliter aliquots of
blood are drawn directly into three evacuated blood
collection tubes, one containing heparin alone (negative
control), one containing T cell mitogens (positive control),
and one containing M. tuberculosis-specific antigens
including early secreted antigenic target 6 and culture
filtrate protein 10 (TB-antigen tube). Following overnight
incubation, 200 mL of plasma is removed from each well and
the concentration of interferon-gamma (IFN-g) is deter-
mined by ELISA. A positive response is defined as an antigen-
nil IFN-g concentration of 0.35 IU/mL.
Diagnosis and treatment of LTBI
From July 2004 toMarch 2008, a positive LTBIwas defined as a
TST induration of 10 mm or, if the induration was <10 mm
but 5 mm, as a positive T-SPOT test [1]. Beginning in April
2008, a positive LTBI was defined as a TST induration of
10 mm or by a positive T-SPOT or QTF-GIT result [5].
In our study subjects, the decision to initiate LTBI
treatment was based on the adequacy of previous anti-TB
treatments and the history of recent contact with patients
with infectious TB, irrespective of the LTBI test results.
When LTBI treatment was indicated, treatment with TNF
antagonists was initiated at least 3 weeks later [12].
Guidelines of the Korean Centers for Disease Control and
Prevention recommend the use of isoniazid (INH) for 9
months, rifampicin (RFP) for 4 months, or both INH and RFP
for 3 months [5]. The selection of these regimens is at the
discretion of each attending physician.
Follow-up
TNF antagonists and LTBI treatments were prescribed
independently by attending physicians and pulmonologists,
respectively. Regardless of their LTBI status, all patients
were scheduled for a follow-up with a pulmonologist for at
least 6 months after completion of TNF antagonist treat-
ment. CXR was usually performed 3 and 9 months after the
initiation of TNF antagonists and every 12 months there-
after. Patients were instructed to visit their pulmonologists
if new symptoms or signs suggestive of TB developed.
Statistical analysis
Continuous variables were compared using Student’s t-
tests, and categorical variables using the c2 or Fisher’s
exact test, as appropriate. All tests of significance were
two sided; p values <0.05 was considered statistically sig-
nificant. All statistical analyses were performed using SPSS
software (version 12.0; SPSS Inc., Chicago, IL).
Results
Characteristics of the study subjects
The mean age of the 101 subjects in the current study
cohort was 40.4  16.0 years and 51 cases (50.5%) weremale. IMIDs included CD in 55 (54.5%), RA in 27 (26.7%), and
AS in 13 (12.9%) patients. Of these 101 cases, 53 (52.5%) had
a history of pulmonary TB, 47 (46.5%) had intestinal TB, and
one (1.0%) had cervical TB lymphadenitis. All 30 patients
(29.7%) who had been tested for human immunodeficiency
virus (HIV) were negative. These clinical characteristics are
presented in Table 1. Patients with a previous history of
anti-TB treatment for intestinal TB were significantly
younger and had more normal CXR findings than the
remaining patients. Most anti-TB treatments were admin-
istered to differentiate between intestinal TB and inflam-
matory bowel diseases in patients with history of intestinal
TB.Diagnosis and treatment of LTBI
Overall, TST results were positive in 22 (21.8%) patients
and IGRA in 45 (44.6%). Patients with a history of intestinal
TB had significantly lower rates of positivity on both tests
(Table 1). Based on positive results from the TST and/or
IGRA tests, 49 (48.5%) patients were determined to have
LTBI. Of the 101 patients in our total cohort, 11 (10.9%)
were started on LTBI treatment. This was due to inade-
quate previous anti-TB treatment in five cases, uncertainty
about previous anti-TB treatment in another five cases,
and recent contact with a patient with infectious pulmo-
nary TB in one case. Five patients were treated with RIF,
four with INH/RIF, and two with INH alone. All 11 patients
completed this LTBI treatment. Table 2 lists the clinical
characteristics of the 101 study subjects in accordance
with whether they received treatment for LTBI. CXR
revealed lesions suggestive of previous TB sequalae in 33
(32.7%) of 101 patients. However, none of these 33 pa-
tients developed active TB. Of the 11 patients in our
cohort treated for LTBI, CXR results showed previous TB
sequalae lesions in 6 cases.Development of TB after initiation of anti-TNF
agents
The median follow-up duration after the initiation of TNF
antagonist treatments of all 101 study subjects and the 90
patients who were not treated for LTBI was 31.5 months
(interquartile range 〔IQR〕 15.3e47.8 months) and 35.2
months (〔IQR〕 17.7e50.0 months), respectively. The
median duration of treatment with TNF antagonists in all
101 patients in the study cohort, the 11 patients treated for
LTBI, and the 90 patients not treated for LTBI was 22.5
months (〔IQR〕9.1e46.7 months), 14.3 months (〔IQR〕
9.1e46.7 months), and 24.7 months (〔IQR〕10.5e46.6
months), respectively.
One patient with AS among the 90 patients who had not
been treated for LTBI developed active pulmonary TB.
This patient had been treated with etanercept and
developed active pulmonary TB 6 years after TNF antag-
onist treatment had been initiated. Overall, only one case
of TB developed in our study cohort during 297 PY of
follow-up, equaling a TB incidence rate of 336 per
100,000 PY.
Table 1 Clinical characteristics of the 101 patients treated with anti-TNF antagonists according to previous TB history.a
Characteristics Total (n Z 101) Patients with history
of intestinal TB
(n Z 47)
Patients with history
of TB other than
intestine (n Z 54)
p-Value
Age (yr) 40.4  16.0 28.9  8.0 50.3  14.7 <0.001
Gender (M/F) 51/50 28/19 23/31 0.112
BMI (kg/m2) 20.1  3.7 18.6  3.0 21.5  3.7 <0.001
CXR findings suggestive of
healed TB
33 (32.7%) 2 (4.3%) 31 (57.4%) <0.001
IMIDs <0.001
Ankylosing spondylitis 13 (12.9%) 0 13 (24.0%)
Rheumatoid arthritis 27 (26.7%) 0 27 (50.0%)
Crohn’s disease 55 (54.5%) 46 (97.9%) 9 (16.7%)
Ulcerative colitis 5 (5.0%) 1 (2.1%) 4 (7.4%)
Psoriasis 1 (1.0%) 0 1 (1.9%)
Anti-TNF agents used <0.001
Etanercept 26 (25.7%) 0 26 (48.1%)
Infliximab 61 (60.4%) 45 (95.7%) 16 (29.6%)
Adalimumab 14 (13.9%) 2 (4.3%) 12 (22.2%)
Anti-inflammatory drugs <0.001
Steroid 14 (13.9%) 9 (19.1%) 5 (9.3%)
DMARDs 12 (11.9%) 0 12 (22.2%)
Steroid þ DMARDs 28 (27.7%) 6 (12.8%) 22 (40.7%)
Otherb 40 (39.6%) 27 (57.4%) 13 (24.1%)
None 7 (6.9%) 5 (10.6%) 2 (3.7%)
Positive TST 22 (21.8%) 2 (4.3%) 20 (37.0%) <0.001
Positive IGRA
T-SPOT.TB (n Z 72) 38 (37.7%) 8/33 (24.2%) 30/39 (76.9%) <0.001
QTF-GIT (n Z 29) 7 (7.0%) 1/14 (7.1%) 6/15 (40.0%) 0.080
Development of TB 1 (1.0%) 0 1 (1.9%) 1.000
Abbreviations: TNF, tumor necrosis factor; TB, tuberculosis; BMI, body mass index; CXR, chest radiography; IMIDs, immune-mediated
inflammatory disease; DMARDs, disease modifying anti-rheumatic drugs; TST, tuberculin skin test; IGRA, interferon-gamma release
assay.
a Means  standard deviations (SD) or number (%) of subjects.
b ‘Other’ includes azathioprine, 6-mercaptopurine, and leflunomide.
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Although some patients in TB endemic areas who are can-
didates for TNF antagonist treatment have a previous his-
tory of TB, little is currently known about the methods of
selecting patients who require LTBI treatment and the
incidence of TB in these patients. To our knowledge, our
present study was the first to investigate the incidence of
TB in patients with a previous history of anti-TB treatment
during anti-TNF therapy. When compared with the inci-
dence rate of TB in patients with IMIDs who have been
treated using TNF blockers with two different LTBI-
diagnosing strategies at our institution (813 per
100,000 PY [1] and 382 per 100,000 PY [5]), the most
important finding of this study was that TNF antagonists can
be administered to patients who had a previous history of
TB with acceptable incidence of TB (336 per 100,000 PY),
after receiving appropriate LTBI treatment based on the
adequacy of previous treatment and recent contact with
patients with active TB in TB-prevalent countries.
Although TST screening for LTBI in patients with a history
of anti-TB treatment is meaningless for selecting candidates
for LTBI treatment, TST and/or IGRA are used to screen forLTBI in patients who are candidates for anti-TNF therapy.
Both tests were performed routinely for some of our current
patients, whereas in other cases they have been performed
as a part of a prospective study [1,5]. However, the decision
to treat LTBI or not was not dependent on the results of these
LTBI tests but on the patient’s medical history, CXR findings,
and recent contact history with individuals with infectious
TB. Following this strategy, anti-TNF agents can be
cautiously used in patients with a previous history of anti-TB
treatment. Within a median follow-up of 31.5 months, only
one patient (1.0%) in our study cohort developed TB. More-
over, the occurrence of TB in this patient 6 years after the
initiation of TNF antagonist treatments suggests that it may
have been due to re-infection and not to a reactivation of
latent foci [13]. This patient was not indicated for LTBI
treatment, since the previous anti-TB treatment had been
adequate and there was no history of recent contact with
patients with infectious TB.
Although all of our study subjects reported a previous
history of TB, it is unlikely that all had true active TB. In-
testinal TB was not confirmed bacteriologically in any of the
patients with this indication but was diagnosed based on
clinical findings alone, such as a colonoscopic appearance.
Table 2 Clinical characteristics of the 101 patients according to whether they received treatment for LTBI.a
Characteristics Total (n Z 101) Patients treated
for LTBI (n Z 11)
Patients not treated
for LTBI (n Z 90)
p-Value
Age (yr) 40.4  16.0 54.4  18.3 38.6  15.0 0.018
Gender (M/F) 51/50 7/4 44/46 0.356
BMI (kg/m2) 20.1  3.7 21.1  3.7 20.0  3.7 0.394
CXR findings suggestive of healed TB 33 (32.7%) 6 (54.5%) 27 (30.0%) 0.170
IMIDs 0.117
Ankylosing spondylitis 13 (12.9%) 2 (18.2%) 11 (12.2%)
Rheumatoid arthritis 27 (26.7%) 6 (54.5%) 21 (23.3%)
Crohn’s disease 55 (54.5%) 2 (18.2%) 53 (58.9%)
Ulcerative colitis 5 (5.0%) 1 (9.1%) 4 (4.4%)
Psoriasis 1 (1.0%) 0 1 (1.1%)
Anti-TNF agents used 0.026
Etanercept 26 (25.7%) 4 (36.4%) 22 (24.4%)
Infliximab 61 (60.4%) 3 (27.3%) 58 (64.4%)
Adalimumab 14 (13.9%) 4 (36.4%) 10 (11.1%)
Anti-inflammatory drugs 0.187
Steroid 14 (13.9%) 2 (18.2%) 12 (13.3%)
DMARDs 12 (11.9%) 0 12 (13.3%)
Steroid þ DMARDs 28 (27.7%) 6 (54.5%) 22 (24.4%)
Otherb 40 (39.6%) 3 (27.3%) 37 (41.1%)
None 7 (6.9%) 0 7 (7.8%)
Positive TST 22 (21.8%) 6 (54.5%) 16 (17.8%) 0.012
Positive IGRA
T-SPOT.TB (n Z 72) 38 (37.7%) 7/7 (100.0%) 31/65 (47.7%) 0.014
QTF-GIT (n Z 29) 7 (7.0%) 3/4 (75.0%) 4/25 (16.0%) 0.034
Development of TB 1 (1.0%) 0 (0%) 1 (1.1%) 1.000
Abbreviations: TNF, tumor necrosis factor; TB, tuberculosis; BMI, body mass index; CXR, chest radiography; IMIDs, immune-mediated
inflammatory disease; DMARDs, disease modifying anti-rheumatic drugs; TST, tuberculin skin test; IGRA, interferon-gamma release
assay.
a Means  standard deviations (SD) or number (%) of subjects.
b ‘Other’ includes azathioprine, 6-mercaptopurine, and leflunomide.
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drugs to differentiate between intestinal TB and IBD, as
suggested by their low rates of positivity on both TST and
IGRA. However, since positivity on LTBI tests has been found
to vary according to underlying diseases in patients without a
previous history of TB [14], the different rates of positivity on
these tests may have been due to differences in underlying
diseases. We also found that patients with CD in our present
cohort had significantly lower rates of positivity on TST (4.9%
vs. 41.2%, p < 0.001) and QTF-GIT (28.8% vs. 63.9%,
p < 0.001) tests than patients with AS (data not shown).
Of the 54 patients in our study cohort with a history of
previous TB other than intestinal TB, 53 cases had pulmonary
TB, with 31 (58.5%) patients having CXR findings suggestive of
prior TB infection sequelae. However, only 37% and 67% were
positive on TST and QFT-GIT tests, respectively, which may
have been due to their high rate of treatment with anti-
inflammatory drugs, including steroids and/or disease
modifying anti-rheumatic drugs. This possibility is supported
by the even higher TST and QFT-GIT positivity rates, 54.6%
and 77.7%, respectively, that were reported among healthy
subjects with a CXR showing of old healed TB lesions [15].
However, only 58.5% of our current patients had CXR findings
suggestive of TB, which may be responsible for the lower
rates of LTBI positivity we observed.Previous studies have reported that the risk of TB is
higher in patients treated with an anti-TNF monoclonal
antibody (infliximab or adalimumab) than in patients
treated with a soluble TNF receptor (etanercept). This is
probably because these treatments act differently on
membrane-bound TNF and thereby have different effects
on effector T cell and Treg cells [16]. The patient in our
present study who developed active pulmonary TB had
been treated with etanercept but as only one of our current
cases developed TB, it was not possible to evaluate
whether any of the anti-TNF agents used in our study cohort
significantly affected the incidence of TB.
Our present study had several noteworthy limitations.
First, all of our patients were from a single referral center
and we analyzed a relatively small number of cases.
Further studies with larger sample sizes are thus needed to
confirm our findings. Second, we obtained the histories of
TB exposure from patient interviews only. Third, two
different LTBI-diagnosing strategies were used sequen-
tially. However, as already mentioned, LTBI test results
were not used to select the candidates for LTBI treatment.
Finally, many of our patient subjects with a history of anti-
TB treatment for intestinal TB may not have actually had
TB. Even after excluding these cases, however, the number
of remaining patients with a previous history of TB (nZ 54)
1802 K.-W. Jo et al.is still one of the largest studied cohorts of patients with TB
who received anti-TNF treatments [5,17].
In conclusion, the results presented here suggest that
patients with IMIDs and a previous history of TB can be
treated with TNF antagonists with acceptable incidence of
TB, after receiving appropriate LTBI treatment if this
choice of therapy is based on the adequacy of previous TB
treatments and a knowledge of recent contact with active
TB in TB-prevalent countries.Conflict of interest statement
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